Navigation Links
Max Neeman International Expands Upon Cardiology and Device Trial Experience to Meet Increased Medical Device Development in India
Date:9/13/2010

RESEARCH TRIANGLE PARK, N.C., Sept. 13 /PRNewswire/ -- Max Neeman International, a leading Indian CRO, announces the expansion of therapeutic focused device clinical trial services in India. Max Neeman has formed an experienced and world class team of medical device experts specializing in carrying out cardiac device trials – therapeutic, diagnostic and surgical. Coronary artherectomy, cardiac stents, aneurysm, mitral valve regurgitation and acute coronary syndrome form 90% of the total device trial experience. These are multicentric global trials with patients as high as 300.  Along with prior experience of conducting device trials, the specialized Max Neeman team and services adds an enhanced level of company expertise in conducting simple to complex device studies.  Max Neeman also has medical device operations and regulatory experience in various other device therapeutic areas as well including CNS and Ophthalmology.

India is emerging as a destination of choice for medical device development and conducting device trials as the market for percutaneous coronary interventions has expanded.  India's device market is currently valued at US $1.7 Billion and projected to grow at the rate of 23% annually.  Benefits which have accelerated outsourcing of device trials to India include: shortened product development cycle, faster time to market (by approximately 30% due to faster patient recruitment) and testing resulting in significant cost savings of about 40-50%.  Max Neeman International conducts device studies for small to large device firms across the globe delivering high quality results at a lower cost resulting in high client satisfaction.  

About Max Neeman International
Max Neeman International is one of the leading and largest CROs in India. Our specialty is that we offer services for the successful conduct of Phase I-IV clinical and device trials for small and mid-sized international and national Pharmaceutical, Biotechnology, Medical Device and Nutraceutical companies in compliance with ICH GCP standards. Operational since 2001, Max Neeman is an ISO 9001:2008 certified CRO for Monitoring, Site Management and Data Management Services. The company is presently active in over 22 cities with 6 regional offices.  Contact Donald Swankie, Vice President of Business Development via email to donald.swankie@neeman-medical.com or call +1.919.424.3345.  For more information please visit www.neeman-medical.com.


'/>"/>
SOURCE Max Neeman International
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Max Neeman International Expands Data Management Services with Conversion Into CDISC Standard Data Model
2. Max Neeman International and AMEDON Collaborate to Increase EDC Performance
3. Max Neeman International Expands Specialized Surgical Team for Clinical Trials
4. PRA Internationals Drug Safety Experts to Speak at Safety Congress
5. Biosystems International Merges With Microbiochips
6. Medizone International Files For Additional Bio-Terrorism Countermeasures Patent Protection
7. International Isotopes Inc. Announces Completion of a Licensing and Permitting Assistance Agreement with URENCO USA
8. Dyadic International and EnGen Bio to Present at Rodman & Renshaw Annual Global Investment Conference
9. Dyadic International Raises Additional $1 Million to Complete $4 Million Convertible Note Offering
10. /C O R R E C T I O N - Mindray Medical International Limited /
11. Ellman International Announces Executive Team Hire
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... , Jan. 19, 2017 Conference Call and Webcast to ... ) today announced it will release results for the fourth quarter ... ... host a conference call at 4:30 PM ET on Wednesday, February ... full year 2016 financial results and other corporate activities. To participate ...
(Date:1/19/2017)... , Jan. 19, 2017 This report ... current and future scenario of the global market. Large ... opioid consumption. Severe chronic constipation is a major side ... traditional laxatives. Hence, novel targeted therapy has been prescribed ... sufferers, launch of targeted medicines, and growing awareness about ...
(Date:1/19/2017)...  Stealth BioTherapeutics Inc. ( Stealth ), a clinical-stage ... announced new additions to its senior leadership team: ... and Daniel Geffken as interim Chief Financial ... , Pharm.D. has been promoted to Chief Clinical Development ... Doug and Daniel to our management team, as both ...
Breaking Medicine Technology:
(Date:1/21/2017)... ... ... Seamild, the largest manufacturer of oats in China, is now aiming at global ... is recognized globally as one of the healthiest cereals, XieQingkui, the founder of Seamild, ... move to sow the seed of good karma. Buddhism spirit featuring benevolence and sacrifice ...
(Date:1/21/2017)... Pekin, IL (PRWEB) , ... January 21, 2017 , ... ... disorders. Even when individuals experience the freedom of recovery, they often feel shame for ... abuse and post-traumatic stress disorder (PTSD). In the workshop, “Rising Strong in Life After ...
(Date:1/20/2017)... ... January 20, 2017 , ... Source Vitál Apothecary, a skin and ... essential oils, announced the company had a successful visit to the 2017 ECRM Diet, ... gives companies that work in the nutritional, sports and health industries a chance to ...
(Date:1/20/2017)... ... January 20, 2017 , ... International Protein, a company based out ... announced it attended the January ECRM trade show in Hilton Head, SC. , ... was determined to create a line of products that would elevate her fitness regime. ...
(Date:1/20/2017)... ... ... “The Angel”: a heartwarming and earnest tale of faith and believing in the ... is the creation of published author, Marjorie Lund-Fontaine, a former professional violinist, alumnus of ... asked of her new book, Marjorie says, “‘The Angel’ was written as a fairytale, ...
Breaking Medicine News(10 mins):